含铂双药方案治疗老年非小细胞肺癌的疗效和安全性分析

Efficacy and safety analysis of platinum doublet chemotherapy on non-small cell lung cancer in the elderly patients

目的观察顺铂联合长春瑞滨、多西他赛或吉西他滨治疗老年非小细胞肺癌的疗效和安全性。方法回顾性研究分别接受长春瑞滨+顺铂、多西他赛+顺铂和吉西他滨+顺铂方案化疗的114例老年非小细胞肺癌的疗效和副反应。结果 3组治疗的有效率分别为35.71%、39.39%、35.9%。副反应以骨髓抑制常见,白细胞减少3级以上者3组分别为26.2%、33.3%、23.1%,3级以上的血小板减少及贫血在全组病例发生率分别为5.26%、0.88%。结论年龄不是含铂双药化疗的禁忌,老年晚期非小细胞肺癌患者可接受含铂的双药方案化疗,并能取得一定近期疗效。

Objective To observe the efficacy and safety of cisplatin plus vinorelbine, doc- etaxel or gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods A total of 114 elderly patients with NSCLC were treated with vinorelbine plus cisplatin（NP）, docetaxel plus cisplatin（DP） and gemcitabine plus cisplatin（GP） chemotherapy respectively. The efficacy and side effects were observed. Results The overall response rate was 35.71% for NP group, 39.39 % for DP group, and 35.9 % for GP group. Common side effects were bone marrow suppression,, leukopenia occured in grade Ⅲ/Ⅳ were 26.2 % in NP group, 33. 3 % in DP group, 23.1% in GP group, thrombocytopenia and anemia occurred in grade Ⅲ/Ⅳ were 5.26 % and 0.88 % in the whole group. Conclusion The dual-drug containing platinum regimens were effective and safe for elderly patients with advanced non-small cell lung cancer patients.